Follow the Pundits

Tag: featured-hedge-funds

Futuristic medical-pharma cityscape with glowing capsules, rising stock arrows, and a giant magnifying glass over Bausch Health, symbolizing deep-value investing and insider buying.

Paulson & Co Keeps Adding to His Bausch Health Stake: Should Investors See Eye to Eye With Him?

Billionaire John Paulson now owns nearly 19% of Bausch Health — and he keeps buying. With improving earnings, low valuation, and high risk, BHC may be a speculative value play worth watching.

Read entire article

Tags: Bausch Health, BHC Stock, Buy or sell BHC, contrarian investing, Contrarian Investment, ContrarianStocks, Debt Risk, featured-hedge-funds, Funanc1al Edge, FUNanc1al Health Hub, Funanc1al Humor, FUNanc1al Investing, FUNanc1al Stocks & Fun, Insider Buying, John Paulson, Paulson & Co, Pharma Stocks, Risks Investing in BHC, Turnaround Stories, Value Stocks, Why Buy BHC
Colorful illustration of a biotech laboratory bench where giant dollar bills swirl around proteomics and genomics machines, while a cartoon Casdin Capital scientist eagerly drops more LAB-branded test tubes into a glowing investment beaker.

Biotech Venture Capital Firm Casdin Keeps Buying Standard BioTools Shares — Time To Invest, Or Time To Label This “Highly Experimental”?

Casdin Capital just scooped up over a million shares of Standard BioTools — again. With strong tech, big cash coming from Illumina, and a major restructuring underway, is this small-cap biotech tools maker a deep-value setup or just another “high-risk, high-lab-cost” gamble? Here’s what’s really going on.

Read entire article

Tags: Biotech Investing, Buy or Sell Lab Stock, Casdin Capital, featured-hedge-funds, FUNanc1al, Funanc1al Edge, genomics, Illumina deal, insider activity, institutional buying, LAB stock, life sciences tools, proteomics, Risks Investing LAB Stock, small-cap stocks, spatial biology, speculative investing, standard biotools, turnaround plays, Why Buy LAB Stock